Heparin - an example in drug safety
Oberpichler-Schwenk, H.
Medizinische Monatsschrift für Pharmazeuten 32(1): 1
2009
ISSN/ISBN: 0342-9601 PMID: 19205131 Document Number: 632960
Document emailed within 1 workday
Related Documents
D'Arcy, P.F. 1999: Reactions and interactions of drugs. Safety measures from Drug Safety Committee of the United Kingdom Journal de Pharmacie de Belgique 54(2): 44-47Alkhunaizi, A.M.; Olyaei, A.J.; Barry, J.M.; deMattos, A.M.; Conlin, M.J.; Lemmers, M.J.; Bennett, W.M.; Norman, D.J. 1998: Efficacy and safety of low molecular weight heparin in renal transplantation Transplantation 66(4): 533-534
White, M.M.; Siders, L.; Jennings, L.K.; White, F.L. 1992: The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia Thrombosis and Haemostasis 68(1): 88
Scarsi, K.K.; Darin, K.M.; Chappell, C.A.; Nitz, S.M.; Lamorde, M. 2016: Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV Drug Safety 39(11): 1053-1072
Dworacka, M.; Nowocień, T. 2017: Undesirable pharmacokinetic drug-to-drug interactions affecting the effectiveness and safety of anti-infectious pharmacotherapy Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 42(248): 61-64
Ecker-Schlipf, B. 1987: Disease and drug abuse. Current problems in drug safety Medizinische Monatsschrift für Pharmazeuten 10(8): 254-261
Burg, M.; Ostendorf, T.; Mooney, A.; Koch, K.M.; Floege, J. 1997: Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety Laboratory Investigation; A Journal of Technical Methods and Pathology 76(4): 505-516
Leonard, B. 1987: Drug safety and drug toxicity: the Irish situation Irish Medical Journal 80(4): 106-107
Buccelletti, E.; Spadaccio, C.; Chello, M.; Marsiliani, D.; Carroccia, A.; Iacomini, P.; Calabrò, G.; Gentiloni Silveri, N.; Franceschi, F. 2011: A critical review of the efficacy and safety in the use of low-molecular-weight heparin in acute ST-elevation myocardial infarction: a Bayesan approach European Review for Medical and Pharmacological Sciences 15(6): 701-710
Nesvold, A.; Kontny, F.; Abildgaard, U.; Dale, J. 1991: Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. a dose-finding study Thrombosis Research 64(5): 579-587
Akanmu, A.S.; Nnodu, O.E.; Giwa, S.O.; Salako, L.A.; Akinsete, I.; Adebule, G.T.; Adekoya-Cole, T.O.; Odunubi, O.O. 2004: Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery African Journal of Medicine and Medical Sciences 33(4): 335-340
Kimbel, K.H. 1978: Drug safety through drug legislation Der Internist 19(6): 326-332
Muraoka, M.; Mochinaga, K.; Sengyoku, H.; Ryu, C.; Ikuta, Y.; Tabuchi, S.; Satou, A.; Inamasu, E.; Tobinaga, S.; Komatsu, H.; Yamaguchi, H.; Kimino, K. 2013: Efficacy and safety of administration of low-dose unfractionated heparin (LDUH) for the prevention of pulmonary thromboembolism after surgery for lung cancer; the long term outcome Kyobu Geka. Japanese Journal of Thoracic Surgery 66(2): 93-100
DeCherney, G.S. 1998: The FDA and drug safety Delaware Medical Journal 70(9): 405-406
Troussard, X.; Mosquet, B.; Bigot, M.C.; Derlon, A.; Khayat, M.C.; Moulin, M.A. 1986: Thrombopenia caused by heparin. Evaluation of cases reported by the Caen-Basse-Normandie Drug Monitoring Center Therapie 41(1): 69-72
Scala, C.; Leone Roberti Maggiore, U.; Remorgida, V.; Venturini, P.L.; Ferrero, S. 2013: Drug safety evaluation of desogestrel Expert Opinion on Drug Safety 12(3): 433-444
Shatin, D.; Gardner, J.S.; Stergachis, A. 1999: Time for action on drug safety JAMA 281(4): 319
Karande, S.; Gogtay, N.J.; Kshirsagar, N.A. 2003: Improving drug safety monitoring Indian Pediatrics 40(12): 1167-1175
Reilly, J. 2014: Drug testing & safety: what's the connection? Occupational Health and Safety 83(9): 80 82
Ovchinnikova, E.A.; Gerasimov, V.B. 2006: Drug safety: from development to clinical use Antibiotiki i Khimioterapiia 51(6): 15-22